The Cell and Gene Therapy Catapult was established in 2012 and exists to advance the growth of the UK’s CGT industry, supporting companies in this space throughout product development and beyond. In Vivo caught up with CEO Matthew Durdy, who took over the role from Keith Thompson in 2020, to learn what the first three years of his tenure have taught him and how he sees the future of advanced therapies progressing.
Matthew Durdy, CEO of the Cell and Gene Therapy Catapult, told In Vivo “two obvious things” have changed in the advance therapies space since he took over the role in spring 2020.
“I walked straight in to the COVID-19 crisis,” he said. “So the first year was all about maintaining an organization...